Japan's Ajinomoto Bio-Pharma Services takes control of GeneDesign

Japan's Ajinomoto Bio-Pharma Services' GeneDesign has expanded it production capabilities for oligonucleotides, the short DNA or RNA molecules oligomers used in gene therapies. (GeneDesign)

Ajinomoto Bio-Pharma Services has concluded a process that will allow the CDMO to operate in the gene therapy space. The company has fully integrated oligonucleotides producer GeneDesign into its operations.

GeneDesign was acquired by Ajinomoto Co. in 2017 but now will be under the control of its small- and large-molecule API producer, Ajinomoto Bio-Pharma Services. The deal comes as GeneDesign has completed a 2,000-square-meter facility that allows it to expand its synthesis and supply of the DNA and RNA molecules up to 10 kg.

RELATED: Ajinomoto Althea expanding GMP production at California facility

Watch the Free Webinar

Chemistry Through Biology: Translating Molecular Biology Technologies into Practical Processes for API Production

Learn about the key advances and critical hurdles in transforming emerging molecular biology technologies into practical applications with commercially viable processes.

“The integration of GeneDesign into Aji Bio-Pharma allows us to more seamlessly support our biopharmaceutical customers globally with a wide range of service offerings in one consolidated supply chain,” Ajinomoto Bio-Pharma Services CEO David Enloe said in a statement.

Gene Design’s new facility at its Osaka campus has space for manufacturing oligonucleotide APIs as well as to custom synthesize heavily modified oligonucleotides, it said. It also has development labs to support manufacturing activities and R&D labs for the development of novel oligonucleotide manufacturing technologies.

The CDMO already produces both small- and large-molecule APIs and intermediates at its sites in Japan, Belgium, India and the U.S. In 2017, it expanded its GMP production at its high-potency products manufacturing facility in San Diego. The CDMO last month said it will spend about $100 million to further expand capabilities at the U.S. site, as well as its site in Belgium.  

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.